FORTREA HOLDINGS INC
FTRENASDAQTrading Snapshot
- Day Range
- $19.28 – $19.83
- 52-Week Range
- $6.07 – $21.39
- Volume
- $5.51B
- Avg Volume
- $6.37B
- Shares Outstanding
- 95.1M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.72B
- Last Q Revenue
- $678M
- P/E Ratio
- —
- P/S Ratio
- 0.7x
- EPS (TTM)
- $-0.91
- Dividend Yield
- —
Why Investors Own FTRE
- ✓High-growth profile — revenue up +13.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About FORTREA HOLDINGS INC
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
TD Cowen Maintains Buy on Fortrea Holdings, Raises Price Target to $23
TD Cowen analyst Charles Rhyee maintains Fortrea Holdings (NASDAQ:FTRE) with a Buy and raises the price target from $19 to $23.
Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $22
Citigroup analyst Brendan Digan maintains Fortrea Holdings (NASDAQ:FTRE) with a Buy and raises the price target from $20 to $22.
Truist Securities Maintains Buy on Fortrea Holdings, Raises Price Target to $26
Truist Securities analyst Jailendra Singh maintains Fortrea Holdings (NASDAQ:FTRE) with a Buy and raises the price target from $19 to $26.
Evercore ISI Group Maintains Outperform on Fortrea Holdings, Raises Price Target to $25
Evercore ISI Group analyst Elizabeth Anderson maintains Fortrea Holdings (NASDAQ:FTRE) with a Outperform and raises the price target from $20 to $25.
Barclays Maintains Equal-Weight on Fortrea Holdings, Raises Price Target to $22
Barclays analyst Luke Sergott maintains Fortrea Holdings (NASDAQ:FTRE) with a Equal-Weight and raises the price target from $18 to $22.
Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcript
Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsTracy Krumme - Senior VP of Investor RelationsAnshul Thakral...